Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Toxicol ; 2017: 8496246, 2017.
Article in English | MEDLINE | ID: mdl-28458688

ABSTRACT

Turoctocog alfa pegol (N8-GP) is a glycoPEGylated human recombinant factor VIII for the treatment of hemophilia A. The safety profile of rFVIII, and polyethylene glycols (PEG) technology, is well-established. Conducting long-term toxicity studies in animals using human proteins can be complicated by anti-drug antibody (ADA) development. To evaluate long-term safety of N8-GP, 26- and 52-week toxicity studies were conducted in immune-deficient rats dosed intravenously every fourth day with 0, 50, 150, 500, or 1200 IU/kg N8-GP. Observations included clinical observations, body weight, ophthalmoscopy, hematology, chemistry, coagulation, urinalysis, toxicokinetics, antibody analysis, and macroscopic/microscopic organ examination. Immunohistochemical staining examined the distribution of PEG in the brain. No adverse test item-related findings were seen and PEG was not detected in the brain. Exposure was confirmed for ~75% of the animals dosed with 500 and 1200 IU/kg N8-GP; the high lower limit of quantification of the bioanalysis assay prevented confirmation of exposure in the lower doses. A small number of animals developed ADAs, and the proportion of animals surviving until scheduled termination was >80%. N8-GP was well tolerated, and the immune-deficient rat proved suitable for testing long-term toxicity of human proteins that are immunogenic in animals.

2.
J Immunol Methods ; 362(1-2): 204-8, 2010 Oct 31.
Article in English | MEDLINE | ID: mdl-20833176

ABSTRACT

Bovine conglutinin is a serum protein involved in innate immunity. It binds calcium dependently to iC3b, a product of the complement component C3 deposited on cell surfaces, immune complexes or artificial surfaces after complement activation. We here present a simple and efficient two-step procedure for the purification of conglutinin. In the first step, bovine serum is incubated with non-coupled chromatographic TSK beads at 37°C to allow complement activation and iC3b deposition on the beads and subsequent binding of conglutinin to iC3b. Conglutinin is then eluted from the beads by EDTA. In the second step, conglutinin is separated from iC3b and IgM by ion-exchange chromatography. This purification procedure yielded 81 µg of conglutinin per ml of serum with a recovery of 61.2%. Surface plasmon resonance analysis showed that the purified conglutinin had a high affinity for mannan (K(d)=2.3-3.2 nM). SDS-PAGE and time-resolved immunofluorometric assays showed that the conglutinin was not contaminated with other serum collectins such as collectin-43 or mannan-binding lectin.


Subject(s)
Collectins/isolation & purification , Complement C3b , Serum Globulins/isolation & purification , Animals , Cattle , Chromatography, Ion Exchange , Collectins/chemistry , Complement Activation , Mannans/chemistry , Serum Globulins/chemistry
3.
Immunogenetics ; 58(2-3): 129-37, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16518621

ABSTRACT

Mannan-binding lectin (MBL) is an innate immune collectin present in the serum of humans and many farm animals. This oligomeric pattern-recognition protein effectively binds to the glycoconjugate arrays present on the surfaces of microorganisms and activates the complement system to enhance pathogen killing and clearance. MBL deficiency is often associated with immunodeficiency in humans. Although two MBLs (MBL-A and MBL-C) have been characterized in various species, the identity of porcine MBL (pMBL) was not clearly defined. In this study, we purified an MBL from porcine serum by mannose affinity, ion exchange, and size exclusion chromatography and determined many of its characteristics. Based on the N-terminal sequence, multiple sequence alignment, and relative affinities to various carbohydrate ligands, we propose that the MBL purified in this study is pMBL-A. We have generated antibodies to this protein and established an immunoassay to quantify pMBL-A in serum. Using this assay, we found breed differences in pMBL-A concentration distributions and heritability estimates. In the Duroc breed (n=588), pMBL-A concentrations show a unimodal distribution with a mean of 9,125 ng/ml. In contrast, the pMBL-A concentration distributions in the Landrace breed (n=533) show three distinct mean values: 301, 2,385, and 11,507 ng/ml. Furthermore, heritability calculations based on an additive genetic variance model with no fixed effects indicate that serum pMBL-A concentration is highly heritable in the Landrace (h (2)=0.8) but not in the Duroc breed (h (2)=0.15). These genetic differences may be useful in selecting breeding pigs for improved disease resistance.


Subject(s)
Breeding , Immunity, Innate/genetics , Mannose-Binding Lectin/blood , Mannose-Binding Lectin/genetics , Sus scrofa/immunology , Amino Acid Sequence , Animals , Antibodies/immunology , Enzyme-Linked Immunosorbent Assay , Mannose-Binding Lectin/chemistry , Molecular Sequence Data , Monosaccharides/chemistry , Sus scrofa/blood , Sus scrofa/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...